Global Diabetic Retinopathy Market 2015-2019
About Diabetic Retinopathy
Diabetic retinopathy is a disorder of the eye that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye on which images are formed. Long-term diabetes affects the retina as high blood glucose levels can damage the tiny blood vessels in the retina. Diabetic retinopathy is broadly classified into non-proliferative diabetic retinopathy and proliferative retinopathy. Treatment for diabetic retinopathy depends on the stage of the disease and is directed toward slowing down or stopping the progression of the disease. Laser surgery, injection of corticosteroids or anti-VEGF drugs into the eye, and vitrectomy are some of the available treatments. One feature of diabetic retinopathy is diabetic macular edema. This is a serious medical condition involving leakage of fluid from the minute, delicate, and previously injured blood vessels located at the back of the eye, which then collects in the macula. This results in inflammation of tissue and blurry vision.
TechNavio's analysts forecast the global diabetic retinopathy market to grow at a CAGR of 6.89% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the global diabetic retinopathy market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of prescribed as well as off-label drugs available in the market. The report also presents the vendor landscape and a corresponding detailed analysis of the four major vendors in the market. In addition, it discusses the major drivers that influence the growth and the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.
TechNavio's report, Global Diabetic Retinopathy Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global diabetic retinopathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.Key Regions
Technavio Announces the Publication of its Research Report – Global Diabetic Retinopathy Market 2015-2019
Technavio recognizes the following companies as the key players in the Global diabetic retinopathy market: Bayer AG, F. Hoffmann-La Roche Ltd. Novartis International AG and Regeneron Pharmaceuticals Inc
Other Prominent Vendors in the market are: Actavis, Alimera Sciences, Ampio Pharmaceuticals, Antisense Therapeutics, BCN Peptides, Boehringer Ingelheim, Glycadia, iCo Therapeutics, Isis Pharmaceuticals, Kowa Group, Lpath, Numoda Capital, OPKO Health, Ohr Pharmaceutical, Parexel International, Promedior, pSivida, Quark Pharmaceuticals, R-Tech Ueno, Sirnaomics and ThromboGenics
Commenting on the report, an analyst from Technavio’s team said: “Launch of novel drugs is one of the key trends being witnessed in the market. The drug pipeline for diabetic retinopathy contains many promising therapies, with a few in the clinical and pre-clinical development stages. The market also has many drugs in the pipeline, including FIC drugs with disease-modifying properties and drugs with better safety and efficacy profiles.”
According to the report, the improvement in the diagnostic procedures is expected to predominantly drive the market. Visual acuity, dilated eye, optical medical imaging, and eye pressure tests are the existing diagnostic tests used by doctors to confirm the presence of diabetic retinopathy.
Further, the report states that availability of effective surgical treatments is a major challenge that the market faces. Specific therapies are required for diabetic retinopathy because of the potential severity of the disease at a later stage, such as proliferative diabetic retinopathy and retinal detachment.
Bayer AG, F Hoffmann-La Roche Ltd. Novartis International AG and Regeneron Pharmaceuticals Inc, Actavis, Alimera Sciences, Ampio Pharmaceuticals, Antisense Therapeutics, BCN Peptides, Boehringer Ingelheim, Glycadia, iCo Therapeutics, Isis Pharmaceuticals, Kowa Group, Lpath, Numoda Capital, OPKO Health, Ohr Pharmaceutical, Parexel International, Promedior, pSivida, Quark Pharmaceuticals, R-Tech Ueno, Sirnaomics, ThromboGenics